HB2346 - 104th General Assembly
| |||||||
| |||||||
| 1 | AN ACT concerning health. | ||||||
| 2 | Be it enacted by the People of the State of Illinois, | ||||||
| 3 | represented in the General Assembly: | ||||||
| 4 | Section 5. The Illinois Drug Reuse Opportunity Program Act | ||||||
| 5 | is amended by changing Sections 5, 45, and 55 and by adding | ||||||
| 6 | Section 70 as follows: | ||||||
| 7 | (410 ILCS 715/5) | ||||||
| 8 | Sec. 5. Definitions. In this Act: | ||||||
| 9 | "Controlled substance" means a drug, substance, or | ||||||
| 10 | immediate precursor in Schedules I through V of 21 CFR 1308. | ||||||
| 11 | "Department" means the Illinois Department of Public | ||||||
| 12 | Health. | ||||||
| 13 | "Dispense" has the same meaning as defined in Section 3 of | ||||||
| 14 | the Pharmacy Practice Act. | ||||||
| 15 | "Donor" means any person, including an individual member | ||||||
| 16 | of the public, or any entity legally authorized to possess | ||||||
| 17 | medicine, including, but not limited to, a wholesaler or | ||||||
| 18 | distributor, third party logistic provider, pharmacy, | ||||||
| 19 | dispenser, clinic, surgical or health center, detention and | ||||||
| 20 | rehabilitation center, jail, prison laboratory, medical or | ||||||
| 21 | pharmacy school, prescriber or other health care professional, | ||||||
| 22 | long-term care facility, or healthcare facility. "Donor" | ||||||
| 23 | includes government agencies and entities that are federally | ||||||
| |||||||
| |||||||
| 1 | authorized to possess medicine, including, but not limited to, | ||||||
| 2 | drug manufacturers, repackagers, relabelers, outsourcing | ||||||
| 3 | facilities, health care facilities operated by the U.S. | ||||||
| 4 | Department of Veterans Affairs, and prisons. | ||||||
| 5 | "Drug" means a prescription drug, over-the-counter drug, | ||||||
| 6 | or supplies needed to administer a prescription or | ||||||
| 7 | over-the-counter drug. | ||||||
| 8 | "Eligible patient" means an individual: | ||||||
| 9 | (1) with a prescription for the drug, if a | ||||||
| 10 | prescription is required to dispense the drug, or who | ||||||
| 11 | reports symptoms treated by the drug if the drug is | ||||||
| 12 | over-the-counter; and | ||||||
| 13 | (2) who is registered with the drug's manufacturer in | ||||||
| 14 | accordance with federal Food and Drug Administration | ||||||
| 15 | requirements, if the registration is required to dispense | ||||||
| 16 | the drug. | ||||||
| 17 | "Manufacturer" has the same meaning as defined in Section | ||||||
| 18 | 15 of the Wholesale Drug Distribution Licensing Act. | ||||||
| 19 | "Pharmacist" means an individual licensed to engage in the | ||||||
| 20 | practice of pharmacy under the Pharmacy Practice Act or | ||||||
| 21 | licensed to engage in the practice of pharmacy in another | ||||||
| 22 | state. | ||||||
| 23 | "Practitioner" means a person licensed in this State to | ||||||
| 24 | dispense or administer drugs or who is licensed in another | ||||||
| 25 | state as a person authorized to dispense or administer drugs. | ||||||
| 26 | "Prescription drug" means any prescribed drug that may be | ||||||
| |||||||
| |||||||
| 1 | legally dispensed by a pharmacy. "Prescription drug" does not | ||||||
| 2 | include a drug for the treatment of cancer that can only be | ||||||
| 3 | dispensed to a patient registered with the drug manufacturer | ||||||
| 4 | in accordance with the federal Food and Drug Administration's | ||||||
| 5 | requirements. | ||||||
| 6 | "Priority patient" means an eligible patient who is an | ||||||
| 7 | Illinois resident and who is indigent, uninsured, | ||||||
| 8 | underinsured, or enrolled in a public health benefits program. | ||||||
| 9 | "Recipient" means any person or entity legally authorized | ||||||
| 10 | to possess medicine with a license or permit in the state in | ||||||
| 11 | which the person or entity is located, including, but not | ||||||
| 12 | limited to, a wholesaler or distributor, reverse distributor, | ||||||
| 13 | repackager, hospital, pharmacy, or clinic. | ||||||
| 14 | "Returns processor" has the same meaning as defined in | ||||||
| 15 | paragraph (18) of 21 U.S.C. 360eee. "Returns processor" | ||||||
| 16 | includes, but is not limited to, a reverse distributor. | ||||||
| 17 | "Unopened tamper-evident packaging" has the same meaning | ||||||
| 18 | as defined in the United States Pharmacopeia (USP) General | ||||||
| 19 | Chapter 659, Packaging and Storage Requirements, including, | ||||||
| 20 | but not limited to, unopened unit-dose, multiple-dose, | ||||||
| 21 | immediate, secondary, and tertiary packaging. | ||||||
| 22 | (Source: P.A. 102-389, eff. 1-1-22.) | ||||||
| 23 | (410 ILCS 715/45) | ||||||
| 24 | Sec. 45. Recordkeeping requirements. When performing any | ||||||
| 25 | action associated with a program under this Act or otherwise | ||||||
| |||||||
| |||||||
| 1 | processing a donated drug for tax, manufacturer, or other | ||||||
| 2 | credit, a recipient shall be considered to be acting as a | ||||||
| 3 | returns processor and shall comply with all recordkeeping | ||||||
| 4 | requirements for nonsalable nonsaleable returns under federal | ||||||
| 5 | law. Records maintained under this Act may be accessed by the | ||||||
| 6 | Department upon request. | ||||||
| 7 | (Source: P.A. 102-389, eff. 1-1-22.) | ||||||
| 8 | (410 ILCS 715/55) | ||||||
| 9 | Sec. 55. Retention of records. All records required under | ||||||
| 10 | this Act shall be retained in physical or electronic format | ||||||
| 11 | and on or off the recipient's premises for a period of 6 years. | ||||||
| 12 | Donors or recipients may contract with one another or a third | ||||||
| 13 | party to create or maintain records on each other's behalf. An | ||||||
| 14 | identifier, such as a serial number or bar code, may be used in | ||||||
| 15 | place of any or all information required by a record or label | ||||||
| 16 | pursuant to this Act if it allows for such information to be | ||||||
| 17 | readily retrievable. Upon request by a State or federal | ||||||
| 18 | regulatory agency, the identifier used for requested records | ||||||
| 19 | shall be replaced with the original information. An identifier | ||||||
| 20 | shall not be used on patient labels when dispensing or | ||||||
| 21 | administering a drug. Records maintained under this Act may be | ||||||
| 22 | accessed by the Department upon request. | ||||||
| 23 | (Source: P.A. 102-389, eff. 1-1-22.) | ||||||
| 24 | (410 ILCS 715/70 new) | ||||||
| |||||||
| |||||||
| 1 | Sec. 70. Program support provided by the Department. | ||||||
| 2 | (a) The Department shall: | ||||||
| 3 | (1) develop, maintain, and publish on its website | ||||||
| 4 | information regarding the names and locations of | ||||||
| 5 | pharmacies participating in the Illinois Drug Reuse | ||||||
| 6 | Opportunity Program; | ||||||
| 7 | (2) educate pharmacies in the State about the Illinois | ||||||
| 8 | Drug Reuse Opportunity Program and how to participate in | ||||||
| 9 | it voluntarily; | ||||||
| 10 | (3) develop and publish educational materials to allow | ||||||
| 11 | program participants and the Department to inform the | ||||||
| 12 | general public about the purposes and benefits of the | ||||||
| 13 | program; and | ||||||
| 14 | (4) collect information from participants and publish | ||||||
| 15 | the information in an annual report to the General | ||||||
| 16 | Assembly by December 31 of each calendar year, beginning | ||||||
| 17 | December 31, 2026. | ||||||
| 18 | (b) Pharmacy recipients shall notify the Department of | ||||||
| 19 | their participation in the dispensing of drugs under this Act | ||||||
| 20 | and shall report any data required in a reasonable format | ||||||
| 21 | established by the Department. | ||||||
